Zobrazeno 1 - 10
of 264
pro vyhledávání: '"A. M. Mendelsohn"'
Autor:
K. B. Gordon, K. Reich, J. J. Crowley, N. J. Korman, F. T. Murphy, Y. Poulin, L. Spelman, P. S. Yamauchi, A. M. Mendelsohn, J. Parno, S. J. Rozzo, C. N. Ellis
Publikováno v:
Journal of Dermatological Treatment, Vol 33, Iss 1, Pp 219-228 (2022)
Background It is unclear whether primary efficacy outcomes in plaque psoriasis clinical trials represent residual disease during treatment. Objectives To evaluate supplementing dichotomous efficacy with residual disease activity. Methods This post ho
Externí odkaz:
https://doaj.org/article/8e86a28160364cbaaf46c5622e281620
Autor:
Joseph B Babigumira, Scott Barnhart, Joanna M Mendelsohn, Vernon Murenje, Mufuta Tshimanga, Christina Mauhy, Isaac Holeman, Sinokuthemba Xaba, Marrianne M Holec, Batsirai Makunike-Chikwinya, Caryl Feldacker
Publikováno v:
PLoS ONE, Vol 15, Iss 9, p e0239915 (2020)
ObjectiveAlthough adverse events (AEs) following voluntary medical male circumcision (VMMC) are rare, their prompt ascertainment and management is a marker of quality care. The use of two-way text messaging (2wT) for client follow-up after VMMC reduc
Externí odkaz:
https://doaj.org/article/3c282b0da83d4fa096e4fd3f9702765f
Autor:
Kalyani Marathe, Joyce M. C. Teng, Scott Guenthner, Christopher G. Bunick, Steven Kempers, Kimmie Eads, Leslie Castelo-Soccio, Alan M. Mendelsohn, Jessica Raiz, Dédée F. Murrell
Publikováno v:
Dermatology and Therapy.
Autor:
Christopher G. Bunick, Joyce M.C. Teng, Scott Guenthner, Kalyani Marathe, Steven Kempers, Kimmie Eads, Leslie Castelo-Soccio, Alan M. Mendelsohn, Jessica Raiz, Dédée F. Murrell
Publikováno v:
Clinical and Experimental Dermatology.
Background Emollients and keratolytics are frequently used to manage symptoms of congenital ichthyosis (CI). Systemic retinoid treatment is complicated by teratogenicity and dose-limiting adverse effects. Objectives This analysis from the randomized
Autor:
Dedee F Murrell, Joyce M C Teng, Scott Guenthner, Kalyani Marathe, Steven Kempers, Kimmie Eads, Leslie Castelo-Soccio, Alan M Mendelsohn, Jessica Raiz, Christopher G Bunick
Publikováno v:
Clinical and Experimental Dermatology.
BackgroundIn two severe congenital ichthyosis subtypes, autosomal recessive lamellar ichthyosis (ARCI-LI) and X-linked recessive ichthyosis (XLRI), cutaneous manifestations include widespread scaling. Approved topical treatment options are limited to
Publikováno v:
Stigma Health
Although scholarly work on the complexity of human sexuality has increasingly been a focus of scholarship, comparatively little research has focused on the phenomenon of mismatch, or discordance, between different aspects of sexuality. This study use
Autor:
Sheryl A Kluberg, Sarah J Willis, Noelle M Cocoros, Susan R Forrow, Emma R Hoffman, Robert M Jin, Aaron M Mendelsohn, Young Hee Nam, Bradford J Gessner, Sarah J Pugh, James H Stark, Cameron T Nutt, Nathan Petrou, Chanu Rhee, Meera Sury, John Aucott
Publikováno v:
Open Forum Infectious Diseases. 9
Background Lyme disease (LD) is the fifth most reported notifiable disease in the US, but the true disease burden remains unknown due to inconsistent reporting. Claims-based algorithms estimate a ≥10-fold higher incidence compared to notifiable-dis
Autor:
Stephen J. Rozzo, Alan M. Mendelsohn, Alice B. Gottlieb, Siba P. Raychaudhuri, Proton Rahman, Saima Chohan, Philip J. Mease, Richard C Chou, Michael E. Luggen, Ferran J Garcia Fructuoso
Publikováno v:
Annals of the Rheumatic Diseases
ObjectivesTo evaluate efficacy and safety of the anti-interleukin-23p19 monoclonal antibody tildrakizumab in patients with psoriatic arthritis (PsA).MethodsIn this randomised, double-blind, placebo-controlled, phase IIb study, patients with active Ps
Autor:
Joyce M.C. Teng, Christopher G. Bunick, Scott Guenthner, Dedee F. Murrell, Kalyani Marathe, Steven Kempers, Kimmie Eads, Alan M. Mendelsohn, Jessica Raiz, Amir Tavakkol, Leslie Castelo-Soccio
Publikováno v:
Journal of the American Academy of Dermatology. 87(6)
Autor:
Jingchuan Zhang, Alan M. Mendelsohn, Joseph F. Merola, Alice B. Gottlieb, Yang Zhao, David M. Pariser, Steven R. Feldman
Publikováno v:
Journal of Dermatological Treatment. 33:1670-1675
To evaluate whether early Psoriasis Area Severity Index (PASI) improvements can predict week 28 tildrakizumab responders and nonresponders.Psoriasis patients pooled from two tildrakizumab phase 3 trials randomized to receive tildrakizumab 100 mg at w